BPC-157
Also known as: Body Protection Compound-157, PL 14736
Quick summary
BPC-157 is a 15-amino-acid sequence derived from a protein found in gastric juice. Research focus: tendon and ligament healing models, muscle crush injury models and angiogenesis and VEGF expression. This page leads with SRP's low-and-slow starting dose.
Amino acid sequence (one-letter code): GEPPPGKPADDAGLV
Overview
BPC-157 is a 15-amino-acid sequence derived from a protein found in gastric juice. It is stable in solution without a carrier, which makes it convenient for animal work. A large body of rodent literature, mostly from the University of Zagreb, looks at tendon, muscle and gut tissue models.
Looking for research material? Simple Research Peptides lists BPC-157 (10 mg Vial) for laboratory research use.
Mechanism
In rodent studies BPC-157 has been linked to the nitric oxide system, to VEGF-related blood-vessel growth and to the FAK–paxillin pathway in tendon cells, so it may act through several routes at once. No single receptor for it has been identified.
Research areas
- tendon and ligament healing models
- muscle crush injury models
- angiogenesis and VEGF expression
- gastrointestinal tissue research
Storage & reconstitution
Supplied as a lyophilized powder; keep sealed, dry and away from light, ideally frozen or refrigerated for long-term holding. Laboratories typically reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, then hold the solution refrigerated (2–8 °C) and use it within the window set by their own stability protocol.
Recommended starting dose (low and slow)
| Starting dose | Low end of the studied range: 250 mcg; 250 mcg; 200 mcg; 250 mcg. |
|---|---|
| Frequency | Commonly reported: once or twice daily subcutaneous use. Figures come from animal work; there are no completed human trials. |
| Reconstitution | Lyophilized powder dissolved in bacteriostatic water; 1 mg = 1,000 mcg, so a 250-500 mcg dose is 0.25-0.5 mg of vial contents. |
Animal work uses ~10 mcg/kg daily (10-50 mcg/kg range, SC/IP/oral); scaled to ~100-700 mcg/day for humans by body-surface-area; common use centers on 200-500 mcg once or twice daily SC, and notes no completed human trials. Typical 4-6 week cycles quoted without a. Its linked references did not match the claims.
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Top of the studied range: 500 mcg; 750 mcg; 500 mcg; 500 mcg. These are range tops, not verified ceilings. |
|---|
Route and timing
Route: Subcutaneous injection; an oral capsule form is listed separately.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Short; animal data suggest well under an hour in the blood.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is BPC-157 studied for?
In research it is studied for tendon and ligament healing models, muscle crush injury models and angiogenesis and VEGF expression. In rodent studies BPC-157 has been linked to the nitric oxide system, to VEGF-related blood-vessel growth and to the FAK–paxillin pathway in tendon cells, so it may act through several routes at once.
How is BPC-157 given in research?
Subcutaneous injection; an oral capsule form is listed separately. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026